Aeris Environmental Ltd (ASX: AEI) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Aeris Environmental Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $24.38 million
P/E Ratio 17.30
Dividend Yield N/A
Shares Outstanding 243.83 million
Earnings per share -0.024
Dividend per share N/A
Year To Date Return -67.21%
Earnings Yield 5.78%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Aeris Environmental Ltd (ASX: AEI)
Latest News

AEI ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Aeris Environmental Ltd

Aeris Environmental Ltd is engaged in the research, development, commercialization of proprietary technologies, and distribution of the AerisGuard products and provides HVAC/R Hygiene and Remediation Technology, and Energy Efficiency services. The company provides various solutions and products such as Aerisview, Aerisguard Polymers, Aeris Smarthub, Bioactive Coil Treatment, Multi Enzyme Coil Cleaner, Surface Treatment, HD Cleaner, and others. Its geographic reportable segments are Australia and International. The company generates a majority of its revenue from Australia.

AEI Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Dec 2021 $0.10 $0.00 0.00% 10,996 $0.10 $0.10 $0.10
01 Dec 2021 $0.10 $0.00 0.00% 111,951 $0.10 $0.10 $0.10
30 Nov 2021 $0.10 $-0.01 -9.52% 1,413,450 $0.10 $0.11 $0.10
29 Nov 2021 $0.11 $0.00 0.00% 137,654 $0.11 $0.11 $0.11
26 Nov 2021 $0.11 $-0.01 -9.09% 22,983 $0.11 $0.11 $0.11
25 Nov 2021 $0.11 $0.00 0.00% 5,000 $0.11 $0.11 $0.11
24 Nov 2021 $0.11 $0.00 0.00% 4,500 $0.11 $0.11 $0.11
23 Nov 2021 $0.11 $0.00 0.00% 27,391 $0.12 $0.12 $0.11
22 Nov 2021 $0.11 $-0.01 -8.70% 71,353 $0.11 $0.11 $0.11
19 Nov 2021 $0.12 $0.01 9.09% 20,800 $0.11 $0.12 $0.11
18 Nov 2021 $0.11 $0.00 0.00% 11,200 $0.12 $0.12 $0.11
17 Nov 2021 $0.11 $-0.01 -8.33% 12,865 $0.12 $0.12 $0.11
16 Nov 2021 $0.12 $0.02 20.00% 381,856 $0.10 $0.12 $0.10
15 Nov 2021 $0.10 $-0.01 -9.09% 460,051 $0.11 $0.11 $0.10
12 Nov 2021 $0.11 $0.00 0.00% 91,847 $0.11 $0.11 $0.11
11 Nov 2021 $0.11 $0.00 0.00% 127,982 $0.11 $0.12 $0.11
09 Nov 2021 $0.11 $0.00 0.00% 136,748 $0.11 $0.12 $0.11
08 Nov 2021 $0.11 $-0.01 -8.70% 446,679 $0.12 $0.12 $0.11

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Maurie Stang Non-Executive ChairmanNon-Executive Director Jul 2002
Mr Stang has more than three decades of experience building and managing companies in the healthcare and biotechnology industry in Australia and internationally. His business development and marketing skills have resulted in the commercialisation of intellectual property across global markets. He is Non-Executive Chairman of Nanosonics Limited since November 2000 and Non-Executive Deputy Chairman of Vectus Biosystems Limited since December 2005. He is Member of Risk Committee and Chair of Corporate Governance Committee.
Mr Steven Kritzler Non-Executive Director Feb 2005
Mr Kritzler holds a number of international patents. He is the Technical Director of Novapharm Research. Mr Kritzler has over 40 years of experience in commercial R&D in the areas of pharmaceutical, medical, cosmetic and specialty industrial products.
Dr Jenny Lee Harry Non-Executive Director Apr 2021
Dr Harry has 20 years' experience in executive management of companies in the biotechnology, diagnostic and biopharmaceutical sectors. She is CEO with experience in growing companies from start-up to commercialisation, and has experience in building teams, establishing global partnerships, capital raising, investor relations, together with corporate governance and compliance. Dr Harry is an experienced Non-Executive Director on the Boards of listed and unlisted companies. She is currently a Non-Executive Director of Neuren Pharmaceuticals Limited and Ondek Pty Ltd, and a member of the Board's IP sub-Committee of the Children's Medical Research Institute. She is Member of Risk Committee and Related Parties Committee.
Mr Peter Bush Chief Financial OfficerAlternate Director Maurie StangChief Executive OfficerExecutive Director Jun 2011
Mr Bush is the Chief Financial Officer of the Regional Health Care Group of companies and of GryphonCapital. He began his career working for five years at BDO and has since spent a number of years working in industry. Mr Bush holds a number of private directorships and board positions.
Mr Michael Ford Non-Executive Director Apr 2020
Mr Ford has over 30 years of experience in Finance and Strategy roles in a range of industries including manufacturing, property and financial services. He is the Chief Financial Officer of News Corp Australia and a Director of Foxtel. Mr Ford is a former Group CFO of QBE Insurance and Deputy CFO of Commonwealth Bank of Australia. He is an experienced Company Director. He is Chair of Risk Committee and Member of Corporate Governance Committee and Related Parties Committee.
Dr Abbie Widin Non-Executive Director Mar 2021
Dr Widin has over 20 years' experience in consumer goods and consulting markets. Dr Widin has held various marketing, commercial and management roles in both private and public companies, such as Procter & Gamble (Australia and Europe), SC Johnson, Reckitt Benckiser and Kellogg. She has strengths in marketing strategy, innovation pipelines and leading cross-functional teams. She is Chair of Related Parties Committee.
Mr Robert John Waring Company Secretary Jul 2002
-
Robert John Waring Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 21,126,051 8.66%
Maurie Stang 20,809,160 8.53%
Bernard Stang 16,152,529 6.62%
National Nominees Limited 12,461,185 5.11%
BNP Paribas Noms Pty Ltd <Drp> 11,090,539 4.55%
Link Traders (Aust) Pty Ltd 10,170,621 4.17%
Steven Kritzler <S Kritzler Family A/C> 8,331,609 3.42%
Girdis Superannuation Pty Ltd <Girdis Super Fund A/C> 6,922,828 2.84%
Potski Pty Ltd <Potski Super Fund A/C> 6,917,604 2.84%
Kefford Holdings Pty Ltd <The Kefford Family A/C> 5,442,000 2.23%
Meditsuper Pty Ltd <Medi Consumables P/L S/F A/C> 4,272,281 1.75%
Development Management & Constructions Pty Ltd 4,247,353 1.74%
Lotsa Nominees Pty Ltd 3,333,333 1.37%
Steven Kritzler <S&J Kritzler Super Fund> 2,921,176 1.20%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 2,446,675 1.00%
Treplo Pty Limited <Stevanne Superannuation A/C> 2,300,000 0.94%
Bennelong Resources Pty Limited <John Egan Super Fund A/C> 2,275,000 0.93%
Radley Investment Co Pty Ltd <John Dailey Super Fund A/C> 2,274,284 0.93%
Bond Street Custodians Limited <Salter D79836 A/C> 2,211,597 0.91%
Henderson International Pty Limited <Henderson Super Fund A/C> 2,133,510 0.88%

Profile

since

Note